IDH2 and acute myeloid leukemia: The phase 3 randomized, open-label IDHENTIFY trial (NCT02577406) compared the efficacy of enasidenib monotherapy to conventional therapies, including azacitidine, low-dose, and intermediate-dose cytarabine, in patients with R/R IDH2-mutated AML.